Odyssey Therapeutics, a biotechnology company pioneering next generation precision immunomodulators and oncology medicines, completed the acquisition of Rahko, a quantum machine learning company. Financial terms were not disclosed. "Rahko's powerful platform will play a direct role in identifying the best leads for our targets with unprecedented speed and accuracy, assisting with our efforts to address the undruggable genome with the goal of delivering transformational impact for patients with inflammatory diseases and cancer in record time," Gary D. Glick, Odyssey Therapeutics Founder and CEO.